Tibsovo Approval Makes Agios’ Second AML Approval In A Year; Priced At $26k For 30 Days
Executive Summary
Tibsovo is the second targeted therapy approved for a mutation-specific subset of relapsed/refractory AML patients. Agios discovered and jointly markets the first, Idhifa, with Celgene.
You may also be interested in...
Finance Watch: As US IPO Market Gets More Challenging, Two Companies Opt Out
Public Company Edition: Five biopharma firms went public in the US in recent weeks, but Inhibrx withdrew its IPO and Monopar postponed its offering. Also, Tot Biopharm launched an IPO in Hong Kong, while Epizyme sold royalties and issued debt to raise up to $270m.
Keeping Track: A Week Of Calm As Shutdown Drags On
The latest drug development news and highlights from our US FDA Performance Tracker.
Top Financings: 2018 Was A Remarkable Year For Biopharma Fundraising
Highlights from the past year's financings include BeiGene's $800m follow-on offering in the US and $903m Hong Kong IPO, Moderna's $560m Series G round and $604m IPO, and Allogene's $300m Series A and $373m IPO.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports